| Systematic (IUPAC) name | |
|---|---|
| (5α,6α)-17-allyl- 7,8-didehydro- 4,5-epoxymorphinan- 3,6-diol | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 62-67-9 |
| ATC code | V03AB02 |
| PubChem | CID 5284595 |
| IUPHAR ligand | 1629 |
| ChemSpider | 4447643 |
| UNII | U59WB2WRY2 |
| ChEMBL | CHEMBL415284 |
| Synonyms | (−)−(5R,6S)-9α-allyl- 4,5-epoxymorphin- 7-en- 3,6-diol |
| Chemical data | |
| Formula | C19H21NO3 |
| Mol. mass | 311.375 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Nalorphine (INN; Lethidrone, Nalline), also known as N-allyl-normorphine, is a mixed opioid agonist-antagonist. It acts at two opioid receptors, at the mu receptor it has antagonistic effects and at the kappa receptors it exerts agonistic characteristics. It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.[1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)